Cargando…

The role of avelumab in advanced urothelial carcinoma in the context of a dynamic treatment landscape

Detalles Bibliográficos
Autores principales:	Koshkin, Vadim S., Basu, Arnab, Grivas, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797653/ https://www.ncbi.nlm.nih.gov/pubmed/35117082 http://dx.doi.org/10.21037/tcr.2018.12.04

Ejemplares similares

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Perioperative chemotherapy for muscle-invasive bladder cancer: the importance of multidisciplinary management for evidence-based practice and transformative research
por: Koshkin, Vadim S., et al.
Publicado: (2018)

Clinical Evaluation of Avelumab in the Treatment of Advanced Urothelial Carcinoma: Focus on Patient Selection and Outcomes
por: Ten Eyck, Jennifer E, et al.
Publicado: (2022)

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
por: Grivas, P., et al.
Publicado: (2023)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

Improving Outcomes for Patients With Advanced Urothelial Carcinoma
por: Grivas, Petros, et al.
Publicado: (2020)

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
por: Powles, Thomas, et al.
Publicado: (2023)

Avelumab demonstrates promise in advanced NSCLC
por: Marciscano, Ariel E., et al.
Publicado: (2017)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Emerging biomarkers in urothelial carcinoma: Challenges and opportunities
por: Andreatos, Nikolaos, et al.
Publicado: (2020)

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region
por: Eto, Masatoshi, et al.
Publicado: (2022)

Changing Body Weight–Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma
por: Novakovic, Ana M., et al.
Publicado: (2019)

Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
por: Wilkins, Justin J., et al.
Publicado: (2019)

HER2 expression in urothelial carcinoma, a systematic literature review
por: Scherrer, Emilie, et al.
Publicado: (2022)

Immunotherapy in Merkel cell carcinoma: role of Avelumab
por: Palla, Amruth R, et al.
Publicado: (2018)

Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry
por: Peak, Taylor, et al.
Publicado: (2023)

Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma
por: Ning, Yang‐Min, et al.
Publicado: (2017)

Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)

Acanthosis Nigricans in a Patient with Urothelial Carcinoma Treated with PD-L1 Inhibitor Avelumab, and Secondary Adrenal Insufficiency
por: Lai, Fei Ya, et al.
Publicado: (2023)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
por: Dietrich, Brian, et al.
Publicado: (2018)

Urothelial Carcinoma
por: Chow, Nan-Haw, et al.
Publicado: (2012)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
por: Strauss, Julius, et al.
Publicado: (2023)

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
por: Tomita, Yoshihiko, et al.
Publicado: (2022)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
por: Tiako Meyo, Manuela, et al.
Publicado: (2022)

Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts
por: Santini, Daniele, et al.
Publicado: (2023)

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019)

Avelumab-induced Pneumonitis in Metastatic Merkel Cell Carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2022)

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
por: Coquan, Elodie, et al.
Publicado: (2022)

Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy
por: Al Homsi, Mohammed U., et al.
Publicado: (2018)

Avelumab for the treatment of locally advanced or metastatic Merkel cell carcinoma—A multicenter real‐world experience in Israel
por: Averbuch, Itamar, et al.
Publicado: (2023)

A review of avelumab in locally advanced and metastatic bladder cancer
por: Rao, Arpit, et al.
Publicado: (2019)

A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
por: Su, Po‐Jung, et al.
Publicado: (2023)

Hematological Toxicity During Concomitant Treatment With Ruxolitinib and Avelumab for Merkel Cell Carcinoma
por: Buonerba, Luciana, et al.
Publicado: (2020)

Hypercalcaemia due to Sarcoidosis during Treatment with Avelumab for Metastatic Merkel Cell Carcinoma
por: Tun Min, Sandy, et al.
Publicado: (2019)

Avelumab for Advanced Merkel Cell Carcinoma: Global Real-World Data on Patient Response and Survival
por: Lohray, Rishabh, et al.
Publicado: (2023)

Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
por: Andric, Zoran, et al.
Publicado: (2023)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_59u6lrm8jcrjh6i6qqv2i9eqpm